Pharmacogenomic study of heart failure and candesartan response from the CHARM programme-Reference-Cited by-同舟云学术

Pharmacogenomic study of heart failure and candesartan response from the CHARM programme

Published:2022-06-23 Issue:5 Volume:9 Page:2997-3008
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Dubé Marie‐Pierre¹²³,Chazara Olympe⁴,Lemaçon Audrey¹²³,Asselin Géraldine¹²,Provost Sylvie¹²,Barhdadi Amina¹²,Lemieux Perreault Louis‐Philippe¹²,Mongrain Ian¹²,Wang Quanli⁴,Carss Keren⁴,Paul Dirk S.⁴,Cunningham Jonathan W.⁵,Rouleau Jean¹³,Solomon Scott D.⁵,McMurray John J.V.⁶,Yusuf Salim⁷,Granger Chris B.⁸,Haefliger Carolina⁴,de Denus Simon¹²⁹,Tardif Jean‐Claude¹³

Affiliation:

1. Montreal Heart Institute Montreal Canada

2. Université de Montréal Beaulieu‐Saucier Pharmacogenomics Centre Montreal Canada

3. Université de Montréal, Faculty of Medicine, Department of medicine Université de Montréal Montreal Canada

4. Centre for Genomics Research (CGR), Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca Cambridge UK

5. Cardiovascular Division, Brigham and Women's Hospital Harvard Medical School Boston MA USA

6. BHF Cardiovascular Research Centre University of Glasgow Glasgow UK

7. The Population Health Research Institute, Hamilton Health Sciences and the School of Rehabilitation Science McMaster University Hamilton ON Canada

8. Duke Clinical Research Institute Duke University School of Medicine Durham NC USA

9. Faculty of Pharmacy Université de Montréal Montreal Canada

Funder

AstraZeneca

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.14026

Reference31 articles.

1. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure

2. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure

3. Effects of Combined Candesartan and ACE Inhibitors on BNP, Markers of Inflammation and Oxidative Stress, and Glucose Regulation in Patients With Symptomatic Heart Failure

4. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

5. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Pharmacogenetics: From Discovery of Genetic Association to Clinical Adoption of Derived Test;Pharmacological Reviews;2024-08-09

2. Influence of genetic characteristics of patients on systolic and diastolic function after acute myocardial infarction: a literature review;Russian Journal of Cardiology;2023-07-21

3. A year in heart failure: updates of clinical and preclinical findings;ESC Heart Failure;2023-04-18